Table 1.
Groups | ||||||
---|---|---|---|---|---|---|
Variables | Conservative (Con) | Pacing | Myectomy (Mye) |
P-value |
||
Con vs. pacing | Con vs. mye | Pacing vs. mye | ||||
n (Female %) | 121 (48) | 88 (52) | 42 (45) | 0.57 | 0.22 | 0.45 |
Age at diagnosis (years) | ||||||
Mean ± SD | 53.9 ± 20.6 | 55.3 ± 18.3 | 32.1 ± 23.0 | |||
Median (IQR) | 59.0 (23.0) | 59.0 (23.0) | 34.4 (40.0) | 0.872 | <0.001 | <0.001 |
Post-diagnosis FU (years) | ||||||
Mean ± SD | 11.3 ± 7.5 | 16.4 ± 8.4 | 19.2 ± 10.2 | |||
Median (IQR) | 9.5 (9.1) | 14.5 (12.9) | 16.3 (16.8) | <0.001 | <0.001 | 0.131 |
NYHA class | ||||||
Mean ± SD | 2.1 ± 0.8 | 2.3 ± 0.6 | 2.0 ± 0.8 | |||
Median (IQR) | 2 (1) | 2 (1) | 2 (1) | 0.350 | 0.242 | 0.050 |
Beta-blocker therapy, n (%) | 88 (73) | 59 (67) | 32 (76) | 0.375 | 0.830 | 0.206 |
Metoprolol dose (mg/day)a | 200 (200) | 100 (100) | 100 (125) | 0.017 | 0.006 | 0.174 |
Verapamil/diltiazem, n (%) | 14 (12) | 14 (16) | 3 (7) | 0.363 | 0.920 | 0.153 |
LVOT gradient (mmHg) | 61 (54) | 64 (66) | 73 (64) | 0.663 | 0.048 | 0.149 |
LVOT gradient >50 mmHg, n (%) | 73 (58) | 60 (68) | 34 (79) | 0.128 | 0.013 | 0.194 |
Septum (mm) , n (%) | 18 (5) | 20 (5) | 18 (7) | 0.031 | 0.429 | 0.051 |
Posterior LV wall (mm), n (%) | 12 (3) | 13 (3) | 12 (5) | 0.147 | 0.772 | 0.527 |
LVEDD (mm), n (%) | 43 (9) | 46 (10) | 42 (7) | 0.047 | 0.233 | 0.021 |
LAD (mm), n (%) | 40 (9) | 44 (13) | 40 (11) | <0.001 | 0.762 | 0.013 |
LVEF (%), n (%) | 69 (15) | 69 (16) | 68 (16) | 0.665 | 0.651 | 0.651 |
Values are represented as median (IQR) where not otherwise specified. P-values: Mann–Whitney U test (inter-group) and χ2 test (categorical variables).
Con, Conservative, medical therapy only; FU, follow-up; IQR, interquartile range; LAD, left atrium diameter; LV, left ventricle; LVEDD, left ventricle end-diastolic diameter; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; n, number; NYHA, New York Heart Association Class; SD, standard deviation.
Metoprolol was the most common beta-blocker used, and thus doses of other beta-blockers have been converted to metoprolol equivalents. P-values in bold indicate significance.